Lupin Limited’s UK subsidiary, Lupin Healthcare, has recently broadcast the launch of their new product, the Luforbec 100/6 dose pressurised metered dose inhaler, which is currently accessible for people in the United Kingdom and with the possibility of additional cost savings via the NHS.
The Luforbec product has been designed as a treatment for adults who experience asthma as well as the medical therapy for serious COPD (chronic obstructive pulmonary disease). Luforbec is relatively similar to Fostair® 100/6 pMDI, they both have matching licensed indications, active ingredients, an extra fine formulation, and device features. Over the last year finishing in May of this year, almost £180 million was spent by the NHS on Fostair® 100/6 pMDI. The Luforbec alternative will provide a financial saving of £8.80 for each prescription.
“Well over 1 million people are currently living with chronic obstructive pulmonary disease“
One fith of people globally are affected by respiratory diseases and it’s currently in the top three biggest causes of death in the UK. Approximately 5.4 million patients are now getting treatment for asthma in the UK alone.
Well over 1 million people are currently living with chronic obstructive pulmonary disease. Both of these diseases create a large cost for the NHS, and it has been projected that asthma accounts for £3 billion annually and COPD cost them £1.9 billion annually.
General Manager for Lupin Healthcare, Ben Ellis, said “We are extremely pleased Luforbec is now available in the UK offering a treatment alternative for healthcare professionals at a reduced cost.”
Respiratory Lead Pharmacist, North Central London Clinical Commissioning Group, Darush Attar-Zadeh, said “I welcome the availability of an alternative pMDI option licensed with a spacer for my patients.”See all the latest jobs in Pharmaceutical